Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Stroop-related cerebellar and temporal activation is correlated with negative affect and alcohol use disorder severity.

Wilcox CE, Clifford J, Ling J, Mayer AR, Bigelow R, Bogenschutz MP, Tonigan JS.

Brain Imaging Behav. 2019 May 22. doi: 10.1007/s11682-019-00126-3. [Epub ahead of print]

PMID:
31115861
2.

Fiscal Stewardship, Choice, and Control: The Context of Self-Directed Services for People With Intellectual and Developmental Disabilities (IDD) in the United States.

Bogenschutz MD, DeCarlo M, Hall-Lande J, Hewitt A.

Intellect Dev Disabil. 2019 Apr;57(2):158-171. doi: 10.1352/1934-9556-57.2.158.

PMID:
30920908
3.

Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca.

Barbosa PCR, Tófoli LF, Bogenschutz MP, Hoy R, Berro LF, Marinho EAV, Areco KN, Winkelman MJ.

Front Psychiatry. 2018 Apr 24;9:136. doi: 10.3389/fpsyt.2018.00136. eCollection 2018.

4.

Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy.

Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, Belser AB, Agin-Liebes G, Bogenschutz MP, Ross S.

Front Pharmacol. 2018 Apr 3;9:256. doi: 10.3389/fphar.2018.00256. eCollection 2018.

5.

A Randomized, Placebo-controlled, Clinical Trial of Prazosin for the Treatment of Alcohol Use Disorder.

Wilcox CE, Tonigan JS, Bogenschutz MP, Clifford J, Bigelow R, Simpson T.

J Addict Med. 2018 Sep/Oct;12(5):339-345. doi: 10.1097/ADM.0000000000000413.

PMID:
29664896
6.

The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions.

Nielson EM, May DG, Forcehimes AA, Bogenschutz MP.

Front Pharmacol. 2018 Feb 21;9:132. doi: 10.3389/fphar.2018.00132. eCollection 2018.

7.

Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.

Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, Ross S, Mennenga SE.

Front Pharmacol. 2018 Feb 20;9:100. doi: 10.3389/fphar.2018.00100. eCollection 2018.

8.

Factors That May Influence Parent Treatment Decision Making for Young Children with Autism Spectrum Disorder.

Dinora P, Bogenschutz M, Lynch K.

J Soc Work Disabil Rehabil. 2017 Jul-Sep;16(3-4):377-395. doi: 10.1080/1536710X.2017.1392395. Epub 2017 Dec 18.

PMID:
29111961
9.

Benefit-cost analysis of SBIRT interventions for substance using patients in emergency departments.

Horn BP, Crandall C, Forcehimes A, French MT, Bogenschutz M.

J Subst Abuse Treat. 2017 Aug;79:6-11. doi: 10.1016/j.jsat.2017.05.003. Epub 2017 May 4.

10.

Therapeutic Applications of Classic Hallucinogens.

Bogenschutz MP, Ross S.

Curr Top Behav Neurosci. 2018;36:361-391. doi: 10.1007/7854_2016_464. Review.

PMID:
28512684
11.

Qualitative and quantitative feedback following workshop training in evidence-based practices: A dissemination study.

Houck JM, Forcehimes AA, Davis MM, Bogenschutz MP.

Prof Psychol Res Pr. 2016 Dec;47(6):413-417. doi: 10.1037/pro0000107. No abstract available.

12.

Psychological and neuropsychological assessment of regular hoasca users.

Barbosa PC, Strassman RJ, da Silveira DX, Areco K, Hoy R, Pommy J, Thoma R, Bogenschutz M.

Compr Psychiatry. 2016 Nov;71:95-105. doi: 10.1016/j.comppsych.2016.09.003. Epub 2016 Sep 12.

PMID:
27653781
13.

It's time to take psilocybin seriously as a possible treatment for substance use disorders.

Bogenschutz MP.

Am J Drug Alcohol Abuse. 2017 Jan;43(1):4-6. doi: 10.1080/00952990.2016.1200060. Epub 2016 Aug 24. No abstract available.

PMID:
27558746
14.

Hair analysis and its concordance with self-report for drug users presenting in emergency department.

Sharma G, Oden N, VanVeldhuisen PC, Bogenschutz MP.

Drug Alcohol Depend. 2016 Oct 1;167:149-55. doi: 10.1016/j.drugalcdep.2016.08.007. Epub 2016 Aug 7.

15.

The RESCueH Programme: Testing New Non-Pharmacologic Interventions for Alcohol Use Disorders: Rationale and Methods.

Søgaard Nielsen A, Nielsen B, Andersen K, Roessler KK, Bühringer G, Bogenschutz M, Ekstrøm CT, Søgaard J; RESCueH Research Group.

Eur Addict Res. 2016;22(6):306-317. Epub 2016 Jul 20.

PMID:
27434091
16.

Coadministration of disulfiram and lorazepam in the treatment of alcohol dependence and co-occurring anxiety disorder: an open-label pilot study.

Bogenschutz MP, Bhatt S, Bohan J, Foster B, Romo P, Wilcox CE, Tonigan JS.

Am J Drug Alcohol Abuse. 2016 Sep;42(5):490-499. Epub 2016 May 16.

17.

The efficacy of attention bias modification therapy in cocaine use disorders.

Mayer AR, Wilcox CE, Dodd AB, Klimaj SD, Dekonenko CJ, Claus ED, Bogenschutz M.

Am J Drug Alcohol Abuse. 2016 Jul;42(4):459-68. doi: 10.3109/00952990.2016.1151523. Epub 2016 May 16.

18.

Outpatient treatment of alcohol use disorders among subjects 60+ years: design of a randomized clinical trial conducted in three countries (Elderly Study).

Andersen K, Bogenschutz MP, Bühringer G, Behrendt S, Bilberg R, Braun B, Ekstrøm CT, Forcehimes A, Lizarraga C, Moyers TB, Nielsen AS.

BMC Psychiatry. 2015 Nov 14;15:280. doi: 10.1186/s12888-015-0672-x.

19.

"It Might Actually Work This Time": Benefits and Barriers to Adapted 12-Step Facilitation Therapy and Mutual-Help Group Attendance From the Perspective of Dually Diagnosed Individuals.

Hagler KJ, Rice SL, Muñoz RE, Salvador JG, Forcehimes AA, Bogenschutz MP.

J Addict Nurs. 2015 Jul-Sep;26(3):120-8; quiz E1. doi: 10.1097/JAN.0000000000000083.

PMID:
26340570
20.

Competency-Based Training and Worker Turnover in Community Supports for People With IDD: Results From a Group Randomized Controlled Study.

Bogenschutz M, Nord D, Hewitt A.

Intellect Dev Disabil. 2015 Jun;53(3):182-95. doi: 10.1352/1934-9556-53.3.182.

PMID:
26107852
21.

Classic hallucinogens in the treatment of addictions.

Bogenschutz MP, Johnson MW.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:250-8. doi: 10.1016/j.pnpbp.2015.03.002. Epub 2015 Mar 14. Review.

PMID:
25784600
22.

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.

Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ.

J Psychopharmacol. 2015 Mar;29(3):289-99. doi: 10.1177/0269881114565144. Epub 2015 Jan 13.

PMID:
25586396
23.

Dose specific effects of olanzapine in the treatment of alcohol dependence.

Littlewood RA, Claus ED, Arenella P, Bogenschutz M, Karoly H, Ewing SW, Bryan AD, Hutchison KE.

Psychopharmacology (Berl). 2015 Apr;232(7):1261-8. doi: 10.1007/s00213-014-3757-1. Epub 2014 Oct 12.

24.

Cognitive control network function in alcohol use disorder before and during treatment with lorazepam.

Wilcox CE, Mayer AR, Bogenschutz MP, Ling J, Dekonenko C, Cumbo H.

Subst Use Misuse. 2015 Jan;50(1):40-52. doi: 10.3109/10826084.2014.957771. Epub 2014 Oct 7.

25.

Direct support workforce supporting individuals with IDD: current wages, benefits, and stability.

Bogenschutz MD, Hewitt A, Nord D, Hepperlen R.

Intellect Dev Disabil. 2014 Oct;52(5):317-29. doi: 10.1352/1934-9556-52.5.317.

PMID:
25247725
26.
27.

Brief intervention for patients with problematic drug use presenting in emergency departments: a randomized clinical trial.

Bogenschutz MP, Donovan DM, Mandler RN, Perl HI, Forcehimes AA, Crandall C, Lindblad R, Oden NL, Sharma G, Metsch L, Lyons MS, McCormack R, Macias-Konstantopoulos W, Douaihy A.

JAMA Intern Med. 2014 Nov;174(11):1736-45. doi: 10.1001/jamainternmed.2014.4052. Erratum in: JAMA Intern Med. 2015 Mar;175(3):470. Macias Konstantopoulos, Wendy [Corrected to Macias-Konstantopoulos, Wendy].

28.

Identifying patients with problematic drug use in the emergency department: results of a multisite study.

Macias Konstantopoulos WL, Dreifuss JA, McDermott KA, Parry BA, Howell ML, Mandler RN, Fitzmaurice GM, Bogenschutz MP, Weiss RD.

Ann Emerg Med. 2014 Nov;64(5):516-25. doi: 10.1016/j.annemergmed.2014.05.012. Epub 2014 Jul 3.

29.

Alcohol, tobacco, and drug use among emergency department patients.

Sanjuan PM, Rice SL, Witkiewitz K, Mandler RN, Crandall C, Bogenschutz MP.

Drug Alcohol Depend. 2014 May 1;138:32-8. doi: 10.1016/j.drugalcdep.2014.01.025. Epub 2014 Feb 12.

30.

12-step facilitation for the dually diagnosed: a randomized clinical trial.

Bogenschutz MP, Rice SL, Tonigan JS, Vogel HS, Nowinski J, Hume D, Arenella PB.

J Subst Abuse Treat. 2014 Apr;46(4):403-11. doi: 10.1016/j.jsat.2013.12.009. Epub 2013 Dec 21.

31.

Cognitive control in alcohol use disorder: deficits and clinical relevance.

Wilcox CE, Dekonenko CJ, Mayer AR, Bogenschutz MP, Turner JA.

Rev Neurosci. 2014;25(1):1-24. doi: 10.1515/revneuro-2013-0054. Review.

32.

Concordance between self-report and urine drug screen data in adolescent opioid dependent clinical trial participants.

Wilcox CE, Bogenschutz MP, Nakazawa M, Woody G.

Addict Behav. 2013 Oct;38(10):2568-74. doi: 10.1016/j.addbeh.2013.05.015. Epub 2013 Jun 13.

34.

Study design to examine the potential role of assessment reactivity in the Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments (SMART-ED) protocol.

Donovan DM, Bogenschutz MP, Perl H, Forcehimes A, Adinoff B, Mandler R, Oden N, Walker R.

Addict Sci Clin Pract. 2012 Aug 28;7:16. doi: 10.1186/1940-0640-7-16.

35.

Test-retest reliability of self-report measures in a dually diagnosed sample.

Houck JM, Forcehimes AA, Gutierrez ET, Bogenschutz MP.

Subst Use Misuse. 2013 Jan;48(1-2):99-105. doi: 10.3109/10826084.2012.731674. Epub 2012 Oct 25.

36.

Health status of ayahuasca users.

Barbosa PC, Mizumoto S, Bogenschutz MP, Strassman RJ.

Drug Test Anal. 2012 Jul-Aug;4(7-8):601-9. doi: 10.1002/dta.1383. Epub 2012 Jul 4. Review.

PMID:
22761152
37.

Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses.

Bogenschutz MP, Pommy JM.

Drug Test Anal. 2012 Jul-Aug;4(7-8):543-55. doi: 10.1002/dta.1376. Epub 2012 Jul 4. Review.

PMID:
22761106
38.

Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth.

Warden D, Subramaniam GA, Carmody T, Woody GE, Minhajuddin A, Poole SA, Potter J, Fishman M, Bogenschutz M, Patkar A, Trivedi MH.

Addict Behav. 2012 Sep;37(9):1046-53. doi: 10.1016/j.addbeh.2012.04.011. Epub 2012 May 8.

39.

Diffusion tensor imaging of white matter networks in individuals with current and remitted alcohol use disorders and comorbid conditions.

Monnig MA, Caprihan A, Yeo RA, Gasparovic C, Ruhl DA, Lysne P, Bogenschutz MP, Hutchison KE, Thoma RJ.

Psychol Addict Behav. 2013 Jun;27(2):455-65. doi: 10.1037/a0027168. Epub 2012 Feb 20.

40.

Community Reinforcement and Family Training: a pilot comparison of group and self-directed delivery.

Manuel JK, Austin JL, Miller WR, McCrady BS, Tonigan JS, Meyers RJ, Smith JE, Bogenschutz MP.

J Subst Abuse Treat. 2012 Jul;43(1):129-36. doi: 10.1016/j.jsat.2011.10.020. Epub 2011 Dec 5.

41.

American Indian methamphetamine and other drug use in the Southwestern United States.

Forcehimes AA, Venner KL, Bogenschutz MP, Foley K, Davis MP, Houck JM, Willie EL, Begaye P.

Cultur Divers Ethnic Minor Psychol. 2011 Oct;17(4):366-76. doi: 10.1037/a0025431.

42.

Compensation effects on clinical trial data collection in opioid-dependent young adults.

Wilcox CE, Bogenschutz MP, Nakazawa M, Woody GE.

Am J Drug Alcohol Abuse. 2012 Jan;38(1):81-6. doi: 10.3109/00952990.2011.600393. Epub 2011 Sep 22.

43.

Design of NIDA CTN Protocol 0047: screening, motivational assessment, referral, and treatment in emergency departments (SMART-ED).

Bogenschutz MP, Donovan DM, Adinoff B, Crandall C, Forcehimes AA, Lindblad R, Mandler RN, Oden NL, Perl HI, Walker R.

Am J Drug Alcohol Abuse. 2011 Sep;37(5):417-25. doi: 10.3109/00952990.2011.596971.

44.

EFFECT OF JOB SKILLS TRAINING ON EMPLOYMENT AND JOB SEEKING BEHAVIORS IN AN AMERICAN INDIAN SUBSTANCE ABUSE TREATMENT SAMPLE.

Foley K, Pallas D, Forcehimes AA, Houck JM, Bogenschutz MP, Keyser-Marcus L, Svikis D.

J Vocat Rehabil. 2010 Oct 26;33(3):181-192.

45.

Perturbation of the glutamate-glutamine system in alcohol dependence and remission.

Thoma R, Mullins P, Ruhl D, Monnig M, Yeo RA, Caprihan A, Bogenschutz M, Lysne P, Tonigan S, Kalyanam R, Gasparovic C.

Neuropsychopharmacology. 2011 Jun;36(7):1359-65. doi: 10.1038/npp.2011.20. Epub 2011 Mar 9. Erratum in: Neuropsychopharmacology. 2012 Apr;37(5):1321.

46.

Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults.

Bogenschutz MP, Abbott PJ, Kushner R, Tonigan JS, Woody GE.

J Addict Med. 2010 Dec;4(4):211-6. doi: 10.1097/ADM.0b013e3181c4e27e.

47.

Status and trends in the direct support workforce in self-directed supports.

Bogenschutz M, Hewitt A, Hall-Lande J, LaLiberte T.

Intellect Dev Disabil. 2010 Oct;48(5):345-60. doi: 10.1352/1934-9556-48.5.345.

PMID:
20973698
48.

Adolescent substance abuse: the effects of alcohol and marijuana on neuropsychological performance.

Thoma RJ, Monnig MA, Lysne PA, Ruhl DA, Pommy JA, Bogenschutz M, Tonigan JS, Yeo RA.

Alcohol Clin Exp Res. 2011 Jan;35(1):39-46. doi: 10.1111/j.1530-0277.2010.01320.x. Epub 2010 Oct 19.

49.

Compounding rifampin suspensions with improved injectability for nasogastric enteral feeding tube administration.

de Villiers MM, Vogel L, Bogenschutz MC, Fingerhut BJ, D'Silva JB, Moore A.

Int J Pharm Compd. 2010 May-Jun;14(3):250-6.

PMID:
23965503
50.

Ethics in substance use disorder treatment.

Geppert CM, Bogenschutz MP.

Psychiatr Clin North Am. 2009 Jun;32(2):283-97. doi: 10.1016/j.psc.2009.03.002. Review.

PMID:
19486814

Supplemental Content

Loading ...
Support Center